<DOC>
	<DOCNO>NCT00322881</DOCNO>
	<brief_summary>The main purpose trial look elderly woman ( 70 year age old ) newly diagnose ovarian , peritoneal , fallopian tube cancer manage six cycle carboplatin paclitaxel , side effect experience , cancer reacts respond standard carboplatin paclitaxel chemotherapy .</brief_summary>
	<brief_title>Carboplatin Paclitaxel Elderly Women With Newly Diagnosed Ovarian , Peritoneal , Fallopian Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary â€¢To determine completion rate six cycle carboplatin/paclitaxel dose reduction toxicity . Secondary - Assess cancer antigen 125 ( CA125 ) response rate paclitaxel/carboplatin group patient - Assess significant toxicity group patient compare non-elderly population . - To determine clinical parameter predict lack completion six cycle carboplatin paclitaxel chemotherapy . - Assess quality life change chemotherapy one year completion chemotherapy . - Assess progression-free survival overall survival group . - To determine feasibility accrual . STATISTICAL DESIGN : Using one sample binomial design , 37 patient 83 % power detect null hypothesis 45 % therapy completion rate versus alternative hypothesis 66 % rate assume one-sided 5 % alpha . The regimen would declare ineffective 19 few patient complete 6 cycle carboplatin paclitaxel chemotherapy without dose adjustment .</detailed_description>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Mixed Tumor , Mesodermal</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Age 70 old Eastern Cooperative Oncology Group ( ECOG ) performance status 0,1 2 medically eligible clinically appropriate receive systemic chemotherapy Diagnosis ovarian , primary peritoneal , fallopian tube cancer , papillary serous cancer endometrium , mixed mesodermal tumor ovary , fallopian tube uterus Life expectancy great 6 month Baseline laboratory value describe protocol Active infection require antibiotic time start chemotherapy Prior pelvic radiotherapy &gt; 25 % bone marrow Any uncontrolled medical problem opinion investigator would preclude safe administration study drug Past history bone marrow transplantation stem cell support Known history central nervous system ( CNS ) metastasis History prior malignancy require prior systemic therapy Clinically significant cardiac disease Uncontrolled diabetes mellitus Any sign intestinal obstruction Participation investigational drug study within three week prior study entry History psychiatric disability central nervous system disorder</criteria>
	<gender>Female</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>carboplatin</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>elderly woman</keyword>
</DOC>